Helus Pharma reports $195.1M cash position and pipeline progress
Helus Pharma (NASDAQ:HELP) reported financial results and clinical progress for the third quarter of fiscal 2026 ended December 31, 2025, highlighting a solid cash position and advancing late-stage programs targeting major psychiatric indications.










